ONE LEVEL DEEPER
MELI
Warren Buffett frameworkThe Owner-OperatorBenjamin Graham frameworkThe Value ArchitectMichael Mauboussin frameworkThe Expectations EngineerHoward Marks frameworkThe Cycle WhispererPeter Lynch frameworkThe Everyday Edge

161% above intrinsic value with -378bp yield spread to treasuries, MercadoLibre shows how euphoria prices perfection into imperfect markets.

cautiousLeaning Bearishconviction

MercadoLibre demonstrates what happens when operational excellence meets valuation extremes — the pendulum has swung too far toward optimism despite the business fundamentals strengthening.

THE LENSES
PRICE VS VALUEovervalued

Is the price above or below what the business is worth?

Price trades 161% above DCF valuation in Q4'25
Reverse DCF implies -1.44% growth despite 39.1% TTM revenue growth
Earnings yield of 0.55% vs 4.33% treasury yield creates -378bp spread
P/E of 45.67x while generating record FCF yield of 4.68%

This framework sees a dangerous disconnect — the price requires the business to shrink (-1.44% implied growth) to justify current valuation, yet revenue grows at 39.1%. When the market prices in impossible assumptions, the risk/reward becomes deeply unfavorable.

Expectations Gap: DCF vs Market
DCF FAIR VALUE
$657
161% premium
MARKET PRICE
$1716
Price implies -1.4% growth · Trailing: 39.1%
THE PENDULUMeuphoric

Where is sentiment — at euphoria or despair?

Institutional ownership increased to 78.9% from 78.0% in Q3'25
Analyst targets converged to tight $2600-$2900 range with $2900 median
Quality earnings beats trigger -5.11% average price drop despite revenue outperformance
213 new institutional positions opened in Q4'25 vs 201 closed

The pendulum has swung toward euphoria — institutions accumulating at record valuations while the market punishes any earnings disappointment. When quality beats produce negative reactions, sentiment has reached dangerous optimism.

Price Targets
2600
low
2900
high
2900
median
2810
consensus
CYCLE TEMPERATUREextended

Where are we in the cycle?

Operating margin expanded from 5.6% in Q4'23 to 10.1% in Q4'25
ROIC improved from -12.33% in Q1'21 to 3.32% in Q4'25
FCF yield at 98th percentile (4.68%) — highest in company history
Revenue at 98th percentile while gross margin at 10th percentile

Multiple metrics at historical extremes signal late-cycle dynamics. The simultaneous peaks in operational efficiency (FCF yield) and valuation multiples while margins compress suggests the cycle has extended beyond sustainable levels.

Operating Margin
ASYMMETRYunfavorable

Does upside significantly exceed downside?

Trading at 40th percentile P/E (45.67x) despite record profitability
Downside to DCF value represents 62% decline from current price
Revenue correlation with inflation (0.952) provides some downside protection
Brazil/Mexico/Argentina concentration (95.6%) amplifies both risks and rewards

Asymmetry is unfavorable — 62% downside to intrinsic value versus limited upside given already-extreme growth assumptions. The emerging market exposure amplifies volatility without compensating upside at these valuations.

P/E Ratio
KEY NUMBERS
VERDICT

Applying this framework reveals a classic pendulum extreme — operational excellence has driven sentiment to euphoria, creating a valuation that requires impossible assumptions. The business generates record cash flows and benefits from the very conditions (high rates, inflation) that should compress its multiple. When insiders sell while institutions chase momentum at 161% above intrinsic value, asymmetry has turned negative. Is this the top of the pendulum's swing?

This analysis applies Howard Marks's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Howard Marks. Educational purposes only. Not financial advice.

OTHER PERSPECTIVES
Warren Buffett framework
The Owner-Operator
Leaning Bullish
Peter Lynch framework
The Everyday Edge
Leaning Bullish
Benjamin Graham framework
The Value Architect
Neutral
Michael Mauboussin framework
The Expectations Engineer
Bearish
Explore
CoStar Group, Inc.CSGPAlnylam Pharmaceuticals, Inc.ALNYExelon CorporationEXCAutomatic Data Processing, Inc.ADPSeagate Technology Holdings plcSTXRegeneron Pharmaceuticals, Inc.REGN
EDUCATIONAL ONLY · NOT FINANCIAL ADVICEv2